New Hope Network is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Eating Away At High Cholesterol Levels

New research in molecular nutrition indicates the importance of diet, including a burgeoning array of functional foods, for reducing cholesterol levels. Ronald P Menskink, PhD, and colleagues Jogchum Plat, PhD, and Daniëlle AJM Kerckhoffs, MSc, explore.

Coronary heart disease (CHD) is still the leading cause of morbidity and mortality in the Western world, but its prognosis has improved substantially during the past decades in part because of our better understanding of CHD's underlying pathology. Researchers have identified many factors, both modifiable and nonmodifiable, that are associated with CHD risk. Much research on CHD risk has focused specifically on the distribution of cholesterol through different lipoproteins. For example, elevated low-density lipoprotein (LDL) levels or low high-density lipoprotein (HDL) levels signal an unfavourable fasting lipoprotein profile. Moreover, evidence is mounting that increased serum triacylglycerol concentration is positively related to cardiovascular risk.1

Diet is a cornerstone for improving unfavourable lipoprotein profiles. Studies continue to support dietary advice that focuses on reducing cholesterol as well as saturated and trans fatty acid intake; eating more vegetables, fruits and whole grains; and preventing obesity.2,3 By achieving these goals, people can often reduce their LDL cholesterol by 10 per cent to 15 per cent. Functional foods offer the promise of further lipid profile improvements.

Most promising for functional foods development are soy protein, soluble fibre, fish oils and plant sterols or stanols, all of which help improve serum lipoprotein profiles.

Soy Isoflavones
The US Food and Drug Administration (FDA) has approved a health claim that 25g soy protein a day, as part of a diet low in saturated fat and cholesterol, may reduce heart disease risk.4 Several dietary intervention trials have shown that when soy consumption increases, serum lipoprotein profiles improve. The precise mechanism for this effect is unknown, but researchers have suggested several possible explanations, including a higher bile acid excretion or enhanced LDL receptor activity.5

Researchers who conducted a meta-analysis published in The New England Journal of Medicine in 1995 estimated that an average daily intake of 47g soy protein, instead of animal protein, lowered serum total and LDL cholesterol concentrations by nine per cent and 13 per cent, respectively, and triacylglycerol by 11 per cent.6 HDL cholesterol concentrations were not affected. Researchers found subjects with high cholesterol levels to be more responsive than those with mildly elevated levels.

In fact, most individual studies involving soy-containing products and subjects with normal or slightly increased total cholesterol levels did not demonstrate a significant serum lipoprotein profile improvement. Therefore, it remains to be resolved whether soy-containing products are only beneficial for significantly hyperlipidemic subjects. Further, it remains to be determined whether soy protein's benefits are the result of soy protein per se or of soy's isoflavones. In the aforementioned meta-analysis, the researchers could not demonstrate a difference in effect between isolated soy protein and textured soy protein. In other studies examined in the meta-analysis, however, researchers suggested that soy's isoflavones account for up to 60 per cent of soy's cholesterol-lowering effects.6

The effects of isolated isoflavones on serum LDL cholesterol concentrations in hypercholesterolemic subjects are, however, not consistent. In one randomised, controlled clinical trial involving 156 healthy men and women, researchers found a significant reduction in serum LDL cholesterol concentrations when subjects ate soy protein with isoflavones compared with soy protein depleted of isoflavones.7 Further, essentially the same findings were described in hypercholesterolemic postmenopausal women.8 In contrast, a third trial with a similar approach did not confirm these findings. In fact, both the isoflavone-rich and isoflavone-poor soy proteins significantly improved the serum lipoprotein profile when compared with protein from casein and non-fat dry milk.9 Also, 80mg isoflavones in supplement form did not induce a significant cholesterol-lowering effect in menopausal and perimenopausal women with normal cholesterol levels.10 However, systemic arterial flexibility was significantly improved.

These conflicting findings do not strongly support the notion that it is just the isoflavones responsible for the potential cholesterol-lowering effect of soy-containing products. It is possible, however, that isoflavones are only effective in combination with other components from soy, such as proteins or saponins.

Viscous Fibres
Dietary fibres, which are resistant to digestion by enzymes in the gastrointestinal tract, can be divided into water-soluble and insoluble fibres. The water-soluble (or viscous) fibres, in particular, have long been recognised for their ability to lower serum cholesterol concentrations. The effective fibre from oats is beta-glucan.11 In 1997, the US FDA approved the health claim that "a diet high in soluble fibre from whole oats and low in saturated fat and cholesterol may reduce the risk of heart disease."12

To achieve a clinically relevant reduction in total serum cholesterol concentrations, a person would have to eat at least 3g beta-glucan per day from oats. Based on a meta-analysis, researchers estimated that such an amount of soluble fibres from oats lowered serum cholesterol concentrations an average of 0.13 mmol/L (5mg/dL) in subjects with a serum cholesterol concentration below 5.9 mmol/L (227mg/dL) and by 0.41 mmol/L (16mg/dL) in hypercholesterolemic subjects.13 In general, researchers did not observe an effect on HDL cholesterol or triacylglycerol concentrations. LDL cholesterol reductions were found to be dose dependent.13,14

Researchers have proposed several mechanisms to explain the cholesterol-lowering effect of beta-glucan. One hypothesis proposes that beta-glucan increases bile acid synthesis because the enterohepatic circulation of bile acids is reduced by intestinal binding of bile acids to beta-glucan.15,16 Alternatively, it is possible that the viscous beta-glucan acts as a physical barrier in the intestinal tract, blocking absorption of bile acids and cholesterol. Other researchers have postulated that soluble fibres are bacterially fermented in the colon, leading to the production of short-chain fatty acids, such as propionate, which may lower hepatic cholesterol synthesis.17

Researchers also have suggested that, particularly in the postprandial state, soluble fibres lower insulin levels, which is also known to lower cholesterol synthesis.18 However, researchers have not found changes in serum cholesterol-precursor concentrations after oat consumption, suggesting that these latter two explanations are not likely correct.19

Numerous well-controlled trials did not demonstrate a beneficial effect of beta-glucan from oats on the serum lipoprotein profile.20-23 Possible explanations for these inconsistent results may be differences in the viscosity of the beta-glucan or detrimental effects of food manufacturing on its viscous characteristics. Elucidating the exact mechanism underlying the cholesterol-lowering effects of beta-glucan may be helpful to explain these apparent discrepancies.

In addition to the soluble fibres from oats, viscous fibres from other sources also may have favourable effects on serum lipoprotein profiles. Beta-glucan from barley and yeast sources, for example, also appear to be effective.24,25

Also in this respect, the US FDA has approved a cholesterol-reducing health claim for psyllium, a soluble fibre isolated from the psyllium seed husk (PSH).26 To achieve a significant reduction in total cholesterol levels, subjects must take at least 10.2g PSH supplying 7g soluble fibre daily (four servings each containing 1.7g soluble fibre) as part of a diet with low saturated fat and cholesterol levels. From three different meta-analyses, taking 9­10g PSH a day lowers serum LDL cholesterol concentrations by 6.0-7.4 per cent. In contrast to beta-glucan, PSH-induced cholesterol reductions do not seem to be associated with initial cholesterol concentrations.27-29

Fish Oils
Two characteristic fatty acids from fish are eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Both EPA (C20:5, n-3) and DHA (C22:6, n-3) are highly unsaturated. Strictly speaking, these two fatty acids are not essential for humans, who can synthesise EPA and DHA from alpha-linolenic acid (C18:3, n-3), a fatty acid mainly found in vegetables. These rates, however, are low.30

Epidemiological studies do suggest that eating more fish has a protective effect, reducing CHD risk.31 Indeed, in dietary intervention studies, researchers have demonstrated that EPA plus DHA lower fasting and postprandial serum triacylgly-cerol concentrations, especially in hypertriglyceridemic subjects; however, if anything, fasting serum LDL and HDL cholesterol concentrations increase slightly.32 These effects on triglycerides are observed at intake levels that can hardly be achieved with regular foods. It is therefore questionable if the possible cardioprotective effect of fish oil can be fully explained by its effects on the serum lipoprotein profile. For example, EPA and DHA also affect other processes such as thrombotic function,33 inflammation34,35 and modification of Na+ channels to prevent ventricular fibrillation36 and consequent sudden cardiac death.37,38 Thus, despite compelling evidence, it is still not known if—and at what intake levels—fish oil affects CHD risk and is hard to ascertain because the precise mechanism of action is not known.

Diet Is The Cornerstone
Improving diet goes a long way toward improving an unfavourable lipoprotein profile, often decreasing LDL cholesterol levels an average of 10 per cent to 15 per cent. HDL cholesterol and triacylglycerol concentrations also may be favourably affected, especially after weight loss. However, for those who do not achieve the desired lipoprotein profile despite strict dietary compliance, functional foods can be beneficial. Soy protein, beta-glucan and psyllium, in particular, are dietary components that may help reduce serum LDL cholesterol concentrations. Diets low in saturated fat, trans fatty acids and cholesterol, along with adequate amounts of soy protein and viscous fibres, may lower LDL cholesterol concentrations between 30 per cent and 35 per cent.39

It is important not only to identify the active food components, but also to understand the mechanisms underlying the effects of these compounds. For this, detailed studies at the molecular level are needed. This relatively new area of molecular nutrition is essential to understanding how nutrition affects metabolic processes and ultimately health. This information is also needed to substantiate possible health claims. Finally, attention should be paid not only to effects on the lipoprotein profile, but also on other health-related parameters that decrease cardiovascular disease risk.


1. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb 1991;11:2-14.

2. Grundy SM. United States cholesterol guidelines 2001: expanded scope of intensive low-density lipoprotein-lowering therapy. Am J Cardiol 2001;88:23J-7J. 3. Kraus RM, et al. AHA dietary guidelines. Revision 2000: a statement for health care professionals from the nutrition committee of the American Heart Association. Circulation 2000;102:2284-99.

4. FDA talk;

5. Potter SM. Soy proteins and serum lipids. Curr Opin Lipidol 1996;7:260-4.

6. Anderson JW, et al. Meta-analysis of the effects of soy protein intake on serum lipids. New Engl J Med 1995;333:276-82.

7. Crouse JR, et al. A randomised trial comparing the effects of casein with that of soy protein containing various amounts of isoflavones on plasma concentrations of lipids and lipoproteins. Arch Intern Med 1999;159:2070-6.

8. Gardner CD, et al. The effect of soy protein with or without isoflavones relative to milk protein on plasma lipids in hypercholesterolemic postmenopausal women. Am J Clin Nutr 2001;73:728-35.

9. Baum JA, et al. Long-term intake of soy protein improves blood lipid profiles and increases mononuclear cell low-density lipoprotein receptor messenger RNA in hypercholesterolemic, postmenopausal women. Am J Clin Nutr 1998;68:545-51.

10. Nestel PJ, et al. Soy isoflavones improve systemic arterial compliance but not plasma lipids in menopausal and perimenopausal women. Arterioscler Thromb Vasc Biol 1997;17:3392-8.

11. Braaten JT, et al. Oat b-glucan reduces blood cholesterol concentrations in hypercholesterolemic subjects. Eur J Clin Nutr 1994;48:465-74.

12. FDA Talk Paper;

13. Ripsin CM, et al. Oat products and lipid lowering. A meta-analysis. JAMA 1992;267:3317-25.

14. Davidson MH, et al. The hypocholesterolemic effects of beta-glucan in oatmeal and oat bran. JAMA 1991;265:1833-9.

15. Kritchevski D, Story JA. Binding of bile salts in vitro by non-nutritive fibre. J Nutr 1974;104:458-64.

16. Bell S, et al. Effect of beta-glucan from oats and yeast on serum lipids. Crit Rev Food Sci Nutr 1999;39:189-202.

17. Thacker PA, et al. Influence of propionic acid on cholesterol metabolism of pigs fed hypercholesterolemic diets. Can J Anim Sci 1981;61:969-75.

18. Bourbon I, et al. Postprandial lipid, glucose, insulin, and cholecystekonin responses in men fed barley pasta enriched with beta-glucan. Am J Clin Nutr 1999;69:55-63.

19. Uusitupa MI, et al. Lathosterol and other non-cholesterol sterols during treatment of hypercholesterolemia with beta-glucan-rich oat bran. Eur J Clin Nutr 1997;51:607-11.

20. Lovegrove JA, et al. Modest doses of b-glucan do not reduce concentrations of potentially atherogenic lipoproteins. Am J Clin Nutr 2000;72:49-55.

21. Torronen R, et al. Effects of an oat bran concentrate on serum lipids in free-living men with mild to moderate hypercholesterolemia. Eur J Clin Nutr 1992;46:621-7.

22. Beer MU, et al. Effects of oat gum on blood cholesterol levels in healthy young men. Eur J Clin Nutr 1996;49:274-5.

23. Leadbetter J, et al. Effects of increasing quantities of oat bran in hypercholesterolemic people. Am J Clin Nutr 1991;54:841-5.

24. McIntosh GH, et al. Barley and wheat foods: influence on plasma cholesterol concentrations in hypercholesterolemic men. Am J Clin Nutr 1991;53:1205-59.

25. Nicolosi R, et al. Plasma lipid changes after supplementation with b-glucan fibre from yeast. Am J Clin Nutr 1999;70:208-12.

26. FDA Talk Paper:

27. Olson BH, et al. Psyllium-enriched cereals lower blood total cholesterol and LDL cholesterol, but not HDL cholesterol, in hypercholesterolemic adults: results of a meta-analysis. J Nutr 1997;127:1973-80.

28. Brown L, et al, Cholesterol-lowering effects of dietary fibre: a meta-analysis. Am J Clin Nutr 1999;69(1):30-42.

29. Anderson JW, et al. Cholesterol-lowering effects of psyllium intake adjunctive to diet therapy in men and women with hypercholesterolemia: analysis of 8 controlled trials. Am J Clin Nutr 2000;71:472-9.

30. Vermunt SHF, et al. Effects of dietary alpha-linolenic acid on the conversion and oxidation of 13C alpha-linolenic acid. Lipids 2000;35(2):137-42.

31. De Deckere EAM, et al. Health aspects of fish and n-3 polyunsaturated fatty acids from plant and marine origin. Eur J Clin Nutr 1998;52:749-53.

32. Kromhout D, et al. The inverse relation between fish consumption and 20 year mortality from coronary heart disease, N Engl J Med 1985;312:1205-9.

33. Harris WS. n-3 Fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 1997;65 (Suppl.):1645S-54S.

34. Knapp H. Dietary fatty acids in human thrombosis and haemostasis. Am J Clin Nutr 1998;65:s1687-s98.

35. De Catarina R, et al. Fatty acid modulation of endothelial activation. Am J Clin Nutr 2000;71(suppl 1):213s-23s.

36. Endres S, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumour necrosis factor by mononuclear cells. N Engl J Med 1989;320:265-71.

37. Das UN. Beneficial effects of n-3 fatty acids in cardiovascular diseases: but why and how? Prost Leko, Ess Fatty Acids 2000;63:352-62.

38. Albert CM, et al. Fish consumption and risk of sudden cardiac death. JAMA 1998;279:23-8.

39. Jenkins DJA, et al. Viscous fibres, health claims, and strategies to reduce cardiovascular risk. Am J Clin Nutr 2001;71:401-2.

Sterols And Stanols Stand Tough

Fruits and vegetables contain health-promoting compounds called phyto-sterols, specifically sterols and stanols. These compounds have been investigated since the 1950s for their cholesterol-lowering effects. Because they've been long recognised as potent science-backed phytochemicals for cholesterol reduction, they've forged a path into functional foods for natural ingredients with cholesterol-lowering properties.

In results of a recent meta-analysis, plant sterols and stanols lowered LDL cholesterol concentrations in a dose-dependent way. HDL cholesterol and triacylglycerol concentrations were not affected. The maximum effect on LDL cholesterol of nine per cent to 14 per cent was reached when intake was between 2g and 2.5g/day.1 These effects were not dependent on dietary cholesterol intake,2 use of cholesterol-lowering medication3 or apoE genotype.4,5 Researchers also theorise that hypercholesterolmic diabetic subjects may benefit from plant stanol esters consumption.6

These and many other findings support the FDA-authorised health claim interim final rule that "a diet low in saturated fat and cholesterol including two servings of foods containing plant sterol or stanol esters—supplying at least 1.3g plant sterols or 3.4g plant stanols a day—may reduce the risk of heart disease."7


1. Law M. Plant sterol and stanol margarines and health. BMJ 2000;320:861-4.

2. Vanhanen HT, et al. Serum cholesterol, cholesterol precursors, and plant sterols in hypercholesterolemic subjects with different apoE phenotypes during dietary sitostanol-ester treatment. J Lipid Res 1993;34:1535-44.

3. Blair S, et al. Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin treatment. Am J Cardiol 2000;86:46-52.

4. Plat J, Mensink RP. Vegetable oil-based versus wood-based stanol ester mixtures: effects on serum lipids and hemostatic factors in non-hypercholesterolemic subjects. Atherosclerosis 2000;148:101-12.

5. Hallikainen MA, et al. Plant stanol esters affect serum cholesterol concentrations of hypercholesterolemic men and women in a dose-dependent manner. J Nutr 2000;130-767-76.

6. Gylling H, Miettinen TA. Serum cholesterol and lipoprotein metabolism in hypercholesterolemic NIDDM patients before and during sitostanol ester-margarine treatment. Diabetologia 1994;37:773-80.

7. FDA Talk Paper;

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.